crenolanib + mitoxantrone + etoposide + cytarabine

**crenolanib + mitoxantrone + etoposide + cytarabine** is an investigational combination therapy comprising four small-molecule drugs: - **Crenolanib** is a potent, selective inhibitor of class III receptor tyrosine kinases, including mutant FLT3, used primarily in the investigational treatment of FLT3-mutated acute myeloid leukemia (AML). - **Mitoxantrone** is a synthetic antineoplastic anthracenedione that intercalates into DNA and inhibits topoisomerase II, disrupting DNA synthesis and repair, leading to cytotoxicity. - **Etoposide** is a topoisomerase II inhibitor that causes DNA strand breaks and blocks cell division by preventing religation of DNA. - **Cytarabine** is an antimetabolite (pyrimidine analog) that is incorporated into DNA, inhibiting DNA polymerase and interfering with DNA synthesis and repair. This combination is primarily investigated for relapsed or refractory acute myeloid leukemia, particularly cases with FLT3 mutation, and is being tested for safety and efficacy in clinical trials[8][2][5].

Other names

MEC plus crenolanib